Skip to main content
Premium Trial:

Request an Annual Quote

Linkage Biosciences Raises $2.1M in Series B Round

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Linkage Biosciences today announced it has raised $2.1 million in a Series B financing round.

The funds will be used to expand manufacturing capabilities, complete regulatory requirements in the US and Europe, and accelerate molecular tests to market, Zachary Antovich, CEO of Linkage, said in a statement.

Fisher Capital and Greenhouse Capital Partners led the round. All major existing investors, including Big Sky Partners, also were participants.

Linkage raised $2 million in a Series A round in 2009.

Based in San Francisco, Linkage's lead product is its LinkSeq HLA product line, which combines a proprietary software and chemistry platform along with real-time PCR instrumentation to provide "significant improvements in the analysis of complex genetic regions," such as an up-to 85 percent reduction in labor requirements, compared to current methods, Linkage said.

Filed under

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.